Richard Larson

Professor

University of Chicago

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Richard Larson is a Professor at the University of Chicago, United States. His research areas primarily focus on acute myeloid leukemia (AML), including treatment strategies such as the use of Magrolimab and azacitidine, as well as genetic risk classification and the efficacy of various therapies for older and relapsed patients. His recent publications highlight significant advancements in the management and understanding of AML, contributing to improved clinical outcomes and addressing disparities in clinical trial participation.

Articles (13)

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (19)

Peter Riedell

University of Chicago

UNITED STATES

Richard Larson

Research Interests

Explore related searches

Contact this professor

About

Articles (13)

Magrolimab plus azacitidine vs physician’s choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study

Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations

Devimistat plus chemotherapy vs chemotherapy alone for older relapsed or refractory patients with AML: results of the ARMADA trial

Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results

Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy

A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT

Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial

Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention

Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial

Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101

Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial

Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors

Therapeutic drug monitoring in oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology consensus guidelines for imatinib therapy

Collaborators (19)

Peter Riedell

Ehab Atallah

Agnieszka Wierzbowska

Charles Craddock

Ellen Ritchie

Stephane De Botton

Gail J. Roboz

Hans Beier Ommen

Wendy Stock

Hee-Je Kim

Heinz Sill

Nikolai A. Podoltsev

Bob Löwenberg

Pau Montesinos

Thomas Pabst

Paresh Vyas

William Clarke

Heidi D. Klepin

Naval G. Daver

Make your next move.